Small-scale neuroendocrine prostate cancer is an advanced prostate cancer that is deadly and very common. This is because patients with adenocarcinoma who are treated with hormonal therapies experience resistance to the administered hormonal therapies.
The cancer spreads to other body parts, especially to the bone or lymph nodes. When the tumors in the new locations are biopsied, the incidence of the small-cell neuroendocrine prostate cancer is found to be high. This suggests that the treatment-associated small-cell neuroendocrine prostate cancer is more common than earlier thought. This discovery was made during an effort to study patients who had accessible metastatic tumors that were hormone resistant and to understand the resistance mechanisms. During the biopsies: • It was noticed that more patients had cases of small-cell neuroendocrine prostate cancers than normal. The scientists sought to characterize the tumor type incidence and describe the gene and genetic expression profiles of the tumors. • Patients with hormone therapy-resistant metastatic cancer were randomly selected. A pathology review was conducted to determine if the tumor had small-cell neuroendocrine features. • Standard imaging tests were conducted, including a picture of the bone and a CT scan to determine the extent of the cancer progression. Later on, an interventional radiologist performed biopsies and reviewed all the scans to identify an accessible spot for biopsy. • Tumors samples were taken out of the metastatic bone biopsies and a subsequent three-month follow-up was made for long-term survival outcomes. • It was concluded that patients would be taken through a second biopsy once their cancer became resistant to the therapy applied. T • It was also found that there’s a subset of 20-30% of patients with hormone-resistant advanced prostate cancer who have gene mutations involved in DNA repair. Genes like BRCA are mutated in prostate cancer too. Finding the small-cell neuroendocrine prostate cancer was exclusive with finding the DNA repair mutations. A follow-up to this study is to develop new medicines and clinical trials based on the data collected in order to improve the outcomes. There’s also the need to find non-invasive markers for the disease. It would also make a huge impact to develop imaging or blood tests that could pick up this type of prostate cancer and make diagnosis easier.
0 Comments
|
AuthorAs the founder and medical director of the Prostate Seed Institute Dr. Gregory A. Echt. His vision to provide the most modern treatment, non surgical treatments for prostate cancer in various locations throughout the Dallas-Fort Worth continues to succeed. Now date, he has made a therapy for prostate implantation seed at over 2,500 men, including urologists and oncologists. Archives
December 2019
Categories |